JPS6130528A - Ｌｐｆ−ｈａの精製方法 - Google Patents
Ｌｐｆ−ｈａの精製方法Info
- Publication number
- JPS6130528A JPS6130528A JP15094584A JP15094584A JPS6130528A JP S6130528 A JPS6130528 A JP S6130528A JP 15094584 A JP15094584 A JP 15094584A JP 15094584 A JP15094584 A JP 15094584A JP S6130528 A JPS6130528 A JP S6130528A
- Authority
- JP
- Japan
- Prior art keywords
- lpf
- gel
- cellulose sulfate
- cellulose
- specific conductivity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 33
- 229920002678 cellulose Polymers 0.000 claims abstract description 27
- 239000001913 cellulose Substances 0.000 claims abstract description 26
- 239000000243 solution Substances 0.000 claims abstract description 18
- 241000588832 Bordetella pertussis Species 0.000 claims abstract description 16
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 15
- 238000010828 elution Methods 0.000 claims abstract description 12
- 239000007853 buffer solution Substances 0.000 claims abstract description 10
- 238000001179 sorption measurement Methods 0.000 claims abstract description 9
- 239000012535 impurity Substances 0.000 claims abstract description 4
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 4
- XZEUAXYWNKYKPL-URLMMPGGSA-N ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 230000001180 sulfating effect Effects 0.000 abstract 1
- 235000010980 cellulose Nutrition 0.000 description 19
- 239000000499 gel Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- -1 sulfate ester Chemical class 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000001766 physiological effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 101001078385 Homo sapiens Haptoglobin Proteins 0.000 description 4
- 201000005702 Pertussis Diseases 0.000 description 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 4
- 235000011613 Pinus brutia Nutrition 0.000 description 4
- 241000018646 Pinus brutia Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 102000050796 human HP Human genes 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 3
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940066827 pertussis vaccine Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000011000 absolute method Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15094584A JPS6130528A (ja) | 1984-07-19 | 1984-07-19 | Ｌｐｆ−ｈａの精製方法 |
| KR1019850005097A KR890001003B1 (ko) | 1984-07-19 | 1985-07-16 | Lpf-ha의 정제방법 |
| AU45093/85A AU571713B2 (en) | 1984-07-19 | 1985-07-17 | Method of purification of lpf-ha from bordetella pertussis |
| DE8585108983T DE3577658D1 (de) | 1984-07-19 | 1985-07-18 | Verfahren zur reinigung vom leukocytosis-foerderungsfaktor haemagglutinin. |
| CA000487035A CA1239104A (en) | 1984-07-19 | 1985-07-18 | Method for the purification of lpf-ha |
| AT85108983T ATE52694T1 (de) | 1984-07-19 | 1985-07-18 | Verfahren zur reinigung vom leukocytosisf¯rderungsfaktor haemagglutinin. |
| EP85108983A EP0170162B1 (en) | 1984-07-19 | 1985-07-18 | Method for the purification of leukocytosis-promoting factor haemagglutinin |
| US07/122,576 US4885359A (en) | 1984-07-19 | 1987-11-16 | Method for the purification of LPF-HA |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15094584A JPS6130528A (ja) | 1984-07-19 | 1984-07-19 | Ｌｐｆ−ｈａの精製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6130528A true JPS6130528A (ja) | 1986-02-12 |
| JPS6241691B2 JPS6241691B2 (en, 2012) | 1987-09-04 |
Family
ID=15507848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15094584A Granted JPS6130528A (ja) | 1984-07-19 | 1984-07-19 | Ｌｐｆ−ｈａの精製方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6130528A (en, 2012) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010250465B2 (en) * | 2009-05-19 | 2014-07-10 | Chikusui Canycom, Inc. | Cutting blade mounting and removal structure for mower |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63269485A (ja) * | 1987-04-27 | 1988-11-07 | Matsushita Electric Ind Co Ltd | 厨房装置 |
-
1984
- 1984-07-19 JP JP15094584A patent/JPS6130528A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010250465B2 (en) * | 2009-05-19 | 2014-07-10 | Chikusui Canycom, Inc. | Cutting blade mounting and removal structure for mower |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6241691B2 (en, 2012) | 1987-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4704274A (en) | Method for the purification of LPF-HA | |
| Kozaki et al. | Purification and some properties of progenitor toxins of Clostridium botulinum type B | |
| US4563303A (en) | Method for purification of filamentous hemagglutinin | |
| JPH01311028A (ja) | 肝炎蛋白質の精製 | |
| JPH0231689A (ja) | 百日咳トキシンの精製法 | |
| US20100055134A1 (en) | Method of separating protective components of bordetella pertussis | |
| JPS6147185A (ja) | 日本脳炎ウイルスの精製方法 | |
| JPH05506649A (ja) | 百日咳菌外膜蛋白質の精製方法 | |
| JPS6147187A (ja) | 狂犬病ウイルスの精製方法 | |
| KR920009730B1 (ko) | 백일해 성분 백신 및 백일해 항원, 디프테리아 톡소이드 및 파상풍 톡소이드의 혼합백신의 제조방법 | |
| JPS6130528A (ja) | Ｌｐｆ−ｈａの精製方法 | |
| JPS6154450A (ja) | 群特異性を有するアフイニテイクロマトグラフイ用ゲルおよびその製造法 | |
| KR890001003B1 (ko) | Lpf-ha의 정제방법 | |
| JPH0423752B2 (en, 2012) | ||
| JPS6153224A (ja) | Ｌｐｆ−ｈａの精製方法 | |
| JPS641447B2 (en, 2012) | ||
| JPS6241692B2 (en, 2012) | ||
| JPS641446B2 (en, 2012) | ||
| JPS60218326A (ja) | 線維状赤血球凝集素の精製方法 | |
| JPS6377900A (ja) | ヤママユガ由来のレクチン様物質及びその分離精製法並びにその用途 | |
| JPH0819159B2 (ja) | 殺菌された抗プラスミン溶液の製造方法 | |
| JPH06209786A (ja) | ヒトパルボウイルス構造タンパク質の精製方法 | |
| DK144179B (da) | Fremgangsmaade til udvinding af streptokokstofskifteprodukter | |
| JPH0235726B2 (en, 2012) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |